
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
ACE CRISPR/Cas9 KO Plasmid (h) | sc-400759 | 20 µg | $397.00 |
Angiotensin-converting enzyme (ACE) is a zinc-dependent dipeptidyl carboxypeptidase that catalyzes conversion of angiotensin I to the vasoactive peptide angiotensin II and degrades bradykinin, positioning it as a central regulator of the renin–angiotensin system. Through modulation of angiotensin II/AT1R signaling, ACE influences vasomotor tone, sodium and fluid balance, oxidative stress, and inflammatory programs that intersect with MAPK and NF-κB-linked responses in vascular and renal tissues. ACE activity contributes to endothelial function and extracellular peptide homeostasis, and altered ACE expression or variants are frequently studied in cardiovascular and renal disease biology. These functions make ACE a useful node for investigating blood pressure regulation, vascular remodeling, and inflammation-associated tissue remodeling in human cell models.
ACE CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the ACE gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the ACE together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the ACE open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish ACE protein expression.
This CRISPR knockout system enables efficient generation of ACE-deficient cell models for investigation of ACE signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
CRISPRs +/- HDRs
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.